+

WO2003047551A1 - Particules agglomerees comprenant un principe actif cotraite avec de la cellulose microcristalline silicifiee - Google Patents

Particules agglomerees comprenant un principe actif cotraite avec de la cellulose microcristalline silicifiee Download PDF

Info

Publication number
WO2003047551A1
WO2003047551A1 PCT/US2001/044928 US0144928W WO03047551A1 WO 2003047551 A1 WO2003047551 A1 WO 2003047551A1 US 0144928 W US0144928 W US 0144928W WO 03047551 A1 WO03047551 A1 WO 03047551A1
Authority
WO
WIPO (PCT)
Prior art keywords
microcrystalline cellulose
dosage form
agglomerated particles
silicified microcrystalline
solid dosage
Prior art date
Application number
PCT/US2001/044928
Other languages
English (en)
Inventor
Robert Sherwood
Joseph A. Zeleznik
David Schaible
Wilhelm Berkulin
Karl-Hans Theissing
Original Assignee
Penwest Pharmaceutical Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penwest Pharmaceutical Company filed Critical Penwest Pharmaceutical Company
Priority to EP01274926A priority Critical patent/EP1509204A4/fr
Priority to AU2002219964A priority patent/AU2002219964A1/en
Priority to PCT/US2001/044928 priority patent/WO2003047551A1/fr
Publication of WO2003047551A1 publication Critical patent/WO2003047551A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • Spray dryers are well known in the art for drying pharmaceutical and nutriceutical active agents and excipients.
  • a spray dryer is used to process fluid materials into powders.
  • the fluid material is introduced into the spray dryer in the form of a solution, suspension, emulsion, slurry, or thin paste.
  • the fluid material is fed from a feed delivery system to an atomizer.
  • the atomizer disperses the fluid material into the drying chamber in fine droplets.
  • a heated air supply applies heated air to the fine droplets in the drying chamber, causing the fine droplets to be dried into a powder, the powder being collected in a collection system.
  • Spray dryers are widely used in the preparation of active agents. For example, it is known to spray dry an active agent in the form of a fluid material (for example, a liquid herbal extract) to form a powder, and thereafter, to blend the powder with conventional tableting agents, and then compress the resulting mixture into a tablet.
  • a fluid material for example, a liquid herbal extract
  • Examples of such tableting agents include lubricants, diluents, binders, disintegrants, and direct compression vehicles.
  • Lubricants are typically added to avoid the material(s) being tableted from sticking to the punches.
  • Commonly used lubricants include magnesium stearate, stearic acid, sodium stearyl fumarate, hydrogenated vegatable oil, and calcium stearate.
  • Such lubricants are commonly included in the final tableted product in amounts of less than 1% by weight.
  • Diluents are frequently added in order to increase the bulk weight of the material to be tableted in order to make the tablet a practical size for compression. This is often necessary where the dose of the drug is relatively small.
  • Binders are agents which impart cohesive qualities to the powdered material(s). Commonly used binders include starch, and sugars such as sucrose, glucose, dextrose, and lactose. Typical disintegrants include starch derivatives and salts of carboxymethylcellulose.
  • Direct compression vehicles include, for example, processed forms of cellulose, sugars, and dicalcium phosphate dihydrate, among others. Microcrystalline cellulose is an example of a processed cellulose that has been utilized extensively in the pharmaceutical industry as a direct compression vehicle for solid dosage forms.
  • Silicified microcrystalline cellulose is a particularly useful direct compression vehicle.
  • Silicified microcrystalline cellulose is a particulate agglomerate of coprocessed microcrystalline cellulose and from about 0.1% to about 20% silicon dioxide, by weight of the microcrystalline cellulose, the microcrystalline cellulose and silicon dioxide being in intimate association with each other, and the silicon dioxide portion of the agglomerate being derived from a silicon dioxide having a particle size from about 1 nanometer (nm) to about 100 microns ( ⁇ m), based on average primary particle size.
  • the silicon dioxide comprises from about 0.5% to about 10% of the silicified microcrystalline cellulose, and most preferably from about 1.25% to about 5% by weight relative to the microcrystalline cellulose.
  • the silicon dioxide preferably has a particle size from about 5 nm to about 40 ⁇ m, and most preferably from about 5 nm to about 50 ⁇ m. Moreover, the silicon dioxide preferably has a surface area from about 10 m 2 g to about 500 m 2 /g, preferably from about 50 m 2 /g to about 500 m 2 /g, and more preferably from about 175 m 2 /g to about 350 m 2 /g.
  • Silicified microcrystalline cellulose, and methods for its manufacture, are described in United States Patent No. 5,585,115, the entire disclosure of which is hereby incorporated by reference. Silificified microcrystalline cellulose is commercially available from Penwest Pharmaceuticals, Inc., under the trademark Prosolv®. Prosolv is available in a number of grades, including, for example, Prosolv SMCC 50, Prosolv SMCC 90, and Prosolv HD.
  • a solid dosage form which includes an active agent and silicified microcrystalline cellulose, the dosage form being formed by a) combining a wetted active agent with dry silicified microcrystalline cellulose in a dryer to form agglomerated particles; and b) incorporating the agglomerated particles into the solid dosage form.
  • step b) comprises co-drying said silicified microcrystalline cellulose, said active agent, and colloidal silicon dioxide in a dryer.
  • the dryer is a spray dryer, and, in certain embodiments, the active agent may be an herbal extract.
  • a solid dosage form which includes an active agent and silicified microcrystalline cellulose, the dosage form being formed by a) providing an active agent suitable for spray drying; b) combining the active agent and silicified microcrystalline cellulose in a spray dryer to form agglomerated particles; and c) incorporating the agglomerated particles into a solid dosage form.
  • the silicified microcrystalline cellulose may be in a slurry, suspension, solution, or emulsion (with or without the active agent) prior to being combined with the active agent in the dryer.
  • the silicified microcrystalline cellulose may be introduced into the dryer in dry form
  • a method of manufacturing a tablet containing an herbal extract comprises: a) providing an .extract composition comprising an herbal extract suitable for spray drying; b) combining the herbal extract with a dry silicified microcrystalline cellulose in a dryer to form agglomerated particles; and c) compressing the agglomerated particles into tablets.
  • an oral solid dosage form which comprises at least about 60 % ginseng extract and from about 25 to about 40% silicified microcrystalline cellulose.
  • a tablet is provided which comprises at least about 60 % St John's Wort extract and from about 25 to about 40% silicified microcrystalline cellulose.
  • a tablet is provided which comprises at least about 60 % artichoke leaves extract and from about 25 to about 40% silicified microcrystalline cellulose.
  • agglomerated particles of an active agent and silicified microcrystalline cellulose are provided, the agglomerated particles being formed by combining the active agent and dry silicified microcrystalline cellulose in a dryer to form agglomerated particles, the agglomerated particles having an average particle size of from about 10 ⁇ m to about 500 ⁇ m. Preferably, the agglomerated particles having an average particle size of from about 15 ⁇ m to about 300 ⁇ m.
  • a tablet comprising an herbal extract and augmented microcrystalline cellulose prepared by spray drying a wetted herbal extract with dry agglomerated particles comprised of microcrystalline cellulose and a compressibility augmenting agent selected from the group consisting of pharmaceutically acceptable colloidal metal oxides and colloidal carbon black.
  • the colloidal metal oxide may be colloidal titanium dioxide.
  • a process for preparing dry extracts from a liquid extract and at least one additional substance by a spray- drying process is characterized in that said at least one additional substance is added to the spray-drying process in a dry form during the spray-drying processes.
  • the agglomerated particles in accordance with certain embodiments of the present mvention described above provide a number of advantages including superior flow characteristics and superior compaction characteristics to prior art compositions.
  • the superior compaction characteristics provided by these embodiments of the present invention allow faster and more efficient processing for tablets, and, moreover, allow a larger percentage of active agent to be included in each tablet.
  • the term "environmental fluid" is meant for purposes of the mvention to encompass, e.g., an aqueous solution, or gastrointestinal fluid.
  • sustained release it is meant for purposes of the invention that a therapeuticaUy active medicament is released from the formulation at a controlled rate such that therapeuticaUy beneficial blood levels (but below toxic levels) of the medicament are maintained over an extended period of time, e.g., providing a 12 hour or a 24 hour dosage form.
  • primary particle size it is meant for purposes of the mvention that the particles are not agglomerated. Agglomeration is common with respect to silicon dioxide particles, resulting in a comparatively average large agglomerated particle size.
  • fluid (or liquid ) material it is meant for purposes of the invention that the material (e.g., the active agent) is sufficiently wetted to be suitable for subsequent spray drying.
  • Figure 1 is a block diagram of a spray dryer including a fluid active agent and a source of silicified microcrystalline cellulose.
  • Figure 2 is a graph of volume flow (ml/s) as a function of aperture size (mm) for the St. John's Wort compositions of Examples 3 and D.
  • Figure 3 is a graph of volume flow (ml/s) as a function of aperture size (mm) for the St. John's Wort compositions of Examples 6, 7, and E.
  • Figure 4 is a graph of moisture uptake for the St. John's wort compositions of Examples 4 and D.
  • Figure 5 is a graph of tablet hardness as a function of compaction force for the compositions of Examples 7 and E.
  • Figure 6 is a graph of tablet hardness as a function of compaction force for the compositions of Examples 8, 9-1, and F.
  • Figure 7 is a graph of tablet hardness as a function of compaction force for the compositions of Examples 9-2, 12, 13, 14, and H.
  • Figure 8 is a graph of moisture uptake for the Ginseng extract compositions of Examples 2 and B.
  • Figure 9 is a graph of mass flow (g/s) as a function of aperture size (mm) for the Ginseng composition of Example 2.
  • Figure 10 is a graph of tablet hardness as a function of compaction force for the compositions of Examples I and 15.
  • Figure 11 is a graph of mass flow (g/s) as a function of aperture size (mm) for the artichoke extract compositions of Examples 1 and A.
  • Figure 12 is a graph of moisture uptake for artichoke extract compositions of Examples 1 and A.
  • Figure 13 is a graph of tablet hardness as a function of compaction force for the compositions of Examples 16 and G .
  • Spray dryers are well known in the art for drying pharmaceutical and nutriceutical active agents and excipients.
  • a spray dryer is used to process fluid materials into powders.
  • the fluid material is introduced into the spray dryer in the form of a solution, slurry, suspension, emulsion, or thin paste.
  • a typical spray dryer including a fluid feed system 1, an atomizer 2, a heated air supply 3, a drying chamber 4, and a collection system 5.
  • the fluid material is fed from the fluid feed system to the atomizer.
  • the atomizer disperses the fluid material into the drying chamber in fine droplets.
  • the heated air supply applies heated air to the fine droplets in the drying chamber, causing the fine droplets to be dried into a powder, the powder being collected in the collection system.
  • fines extremely fine particles that float up from the collection system (referred to in the art as "fines") are recycled back into the path of the atomized fluid material.
  • the fluid material is an active agent, and silicified microcrystalline cellulose from (hereinafter "silicified MCC") from, for example a source of silicified MCC 6, is fed into the drying chamber 4 and is interdispersed with the atomized fluid material as the heat 3 is applied. As the atomized fluid material dries, it is combined with the silicified MCC so that the powder collected in the collection system 5 includes agglomerated particles of active agent/silicified MCC.
  • silicified MCC silicified microcrystalline cellulose from
  • fluid (or liquid ) material it is meant that the material (e.g., the active agent) is sufficiently wetted to be suitable for subsequent spray drying.
  • the material e.g., the active agent
  • the material may be in a solution, a suspension, a slurry, or an emulsion.
  • the solution may include one or more of a variety of solvents, including water, alcohol, ethanol, and the like. Hydro-alcohol solvents may also be used.
  • dry silicified MCC is fed into the drying chamber.
  • a slurry of silicified MCC e.g., a slurry of Prosolv SMCC 90
  • the silicified MCC slurry is fed into the drying chamber as an atomized silicified MCC fluid.
  • the silicified MCC slurry can be introduced into the drying chamber separately from the atomized active fluid material (e.g., through a separate spray nozzle), or the silicified MCC can be combined with the active fluid material prior to atomization (e.g., as a slurry in the fluid feed system), and the active fluid material and silicified MCC could be atomized together.
  • the dry silicified MCC may be fed into the drying chamber along with the recycled fines.
  • the silicified MCC is preferably fed into the drying chamber at a rate sufficient to cause the agglomerated particles to contain at least about 25 % silicified MCC, and preferably at least about 30 % silicified MCC. Most preferably, the silicified MCC is fed into the drying chamber at a rate sufficient to cause the agglomerated particles to contain from about 30 % to about 40 % silicified MCC.
  • dry colloidal silicon dioxide is also fed into the drying chamber and is interdispersed with the silicified MCC and the atomized fluid material.
  • the colloidal silicon dioxide may be fed into the drying chamber as an atomized silicon dioxide fluid (e.g., from a slurry).
  • the resulting agglomerated particles are agglomerated particles of active agent/silicified MCC/colloidal silicon dioxide.
  • the silicified MCC and colloidal silicon dioxide is fed into the drying chamber at a rate sufficient to cause the agglomerated particles to contain about 25 % silicified MCC and about 5 % colloidal silicon dioxide.
  • silicified MCC is a particulate agglomerate of coprocessed microcrystalline cellulose and from about 0.1% to about 20% silicon dioxide, by weight of the microcrystalline cellulose, the microcrystalline cellulose and silicon dioxide being in intimate association with each other, and the silicon dioxide portion of the agglomerate being derived from a silicon dioxide having a particle size from about 1 nanometer (nm) to about 100 microns ( ⁇ m), based on average primary particle size.
  • intimate association it is meant that the silicon dioxide has in some manner been integrated with the microcrystalline cellulose particles, e.g., via a partial coating of the microcrystalline particles, as opposed to a chemical interaction of the two ingredients.
  • the term "intimate association" is therefore deemed for purposes of the present description as being synonymous with "integrated” or "united".
  • the coprocessed particles are not necessarily uniform or homogeneous. Rather, under magnification, e.g., scanning electron microscope at 500 times, the silicon dioxide at the preferred percent inclusion appears to be an "edge-coating".
  • the silicon dioxide comprises from about 0.5% to about 10% of the silicified MCC, and most preferably from about 1.25% to about 5% by weight relative to the microcrystalline cellulose.
  • the silicon dioxide preferably has a particle size from about 5 nm to about 40 ⁇ m, and most preferably from about 5 nm to about 50 ⁇ m.
  • the silicon dioxide preferably has a surface area from about 10 m 2 g to about 500 m 2 /g, preferably from about 50 m 2 /g to about 500 m 2 /g, and more preferably from about 175 m 2 /g to about 350 m 2 /g.
  • Silicified MCC and methods for its manufacture, are described in United States Patent No. 5,585,115, the entire disclosure of which is hereby incorporated by reference.
  • Silificified microcrystalline ceUulose is commercially available from Penwest Pharmaceuticals, Inc., under the trademark Prosolv®.
  • Prosolv is available in a number of grades, including, for example, Prosolv SMCC 50, Prosolv SMCC 90, and Prosolv HD, each of which contains 2 % colloidal silicon dioxide, by weight relative to the microcrystalline cellulose.
  • Colloidal silicon dioxide is a submicron fumed silica prepared by the vapor-phase hydrolysis (e.g., at 1110° C.) of a silicon compound, such as silicon tetrachloride.
  • a silicon compound such as silicon tetrachloride.
  • the product itself is a submicron, fluffy, light, loose, bluish- white, odorless and tasteless amorphous powder which is commercially available from a number of sources, including Cabot Corporation (under the tradename Cab-O-Sil); Degussa, Inc. (under the tradename Aerosil); E. I. DuPont & Co.; and W. R. Grace & Co.
  • Colloidal silicon dioxide is also known as colloidal silica, fumed silica, light anhydrous silicic acid, silicic anhydride, and silicon dioxide fumed, among others.
  • a variety of commercial grades of colloidal silicon dioxide are produced by varying the manufacturing process. These modifications do not affect the silica content, specific gravity, refractive index, color or amorphous form. However, these modifications are known to change the particle size, surface areas, and bulk densities of the colloidal silicon dioxide products.
  • the surface area of the preferred class of silicon dioxides utilized in the invention ranges from about 50 m 2 /gm to about 500 m 2 /gm.
  • the average primary particle diameter of the preferred class of silicon dioxides utilized in the invention ranges from about 5 nm to about 50 nm. However, in commercial colloidal silicon dioxide products, these particles are agglomerated or aggregated to varying extents.
  • the bulk density of the preferred class of silicon dioxides utilized in the invention ranges from about 20 g/1 to about 100 g/1.
  • colloidal silicon dioxide products have, for example, a BET surface area ranging from about 50 +- 15 m 2 /gm (Aerosil OX50) to about 400 +- 20 (Cab-O-Sil S-17) or 390 +- 40 m 2 /gm (Cab-O-Sil EH-5).
  • particle sizes range from a nominal particle diameter of 7 nm (e.g., Cab-O-Sil S-17 or Cab-O-Sil EH-5) to an average primary particle size of 40 nm (Aerosil OX50).
  • the density of these products range from 72.0 +- 8 g/1 (Cab-O-Sil S-17) to 36.8 g/1 (e.g., Cab-O-Sil M-5).
  • the pH of the these products at 4% aqueous dispersion ranges from pH 3.5-4.5.
  • colloidal silicon dioxide is surface treated silica, including, for example, hydrophobically modified silica and hydrophilically modified silica.
  • hydrophobically modified silica is AEROSIL® R 972, manufactured by Degussa AG.
  • the active agent(s) which may be used in accordance with the embodiments described above include systemically active therapeutic agents, locally active therapeutic agents, disinfecting agents, chemical impregnants, cleansing agents, deodorants, fragrances, dyes, animal repellents, insect repellents, fertilizing agents, pesticides, herbicides, fungicides, plant growth stimulants, and the like.
  • the therapeuticaUy active agents include both water soluble and water insoluble drugs.
  • therapeuticaUy active agents include antihistamines (e.g., dimenhydrinate, diphehhydramine, chlorpheniramine and dexchlorpheniramine maleate), analgesics (e.g., aspirin, codeine, morphine, dihydromorphone, oxycodone, etc.), non-steroidal anti-inflammatory agents (e.g., naproxyn, diclofenac, indomethacin, ibuprofen, sulindac), anti-emetics (e.g., metoclopramide), anti-epileptics (e.g., phenytoin, meprobamate and nitrezepam), vasodilators (e.g., nifedipine, papaverine,
  • antihistamines e.g., dimenhydrinate, diphehhydramine, chlorpheniramine and dexch
  • antacids e.g. atropine, scopolamine
  • antidiabetics e.g., insulin
  • diuretics e.g., ethacrynic acid, bendrofluazide
  • anti-hypotensives e.g., propranolol, clonidine
  • antihypertensives e.g, clonidine, methyldopa
  • bronchodilators e.g., albuterol
  • steroids e.g., hydrocortisone, triamcinolone, prednisone
  • antibiotics e.g., tetracycline
  • antihemorrhoidals hypnotics, psychotropics, antidiarrheals, mucolytics, sedatives, decongestants, laxatives, vitamins, stimulants (including appetite suppressants such as phenylpropanolamine).
  • appetite suppressants such as phenylpropanolamine
  • locally active agents can be used in conjunction with the embodiments described herein, and include both water soluble and water insoluble agents.
  • the locally active agent(s) is intended to exert its effect in the environment of use, e.g., the oral cavity, although in some instances the active agent may also have systemic activity via absorption into the blood via the surrounding mucosa.
  • the locally active agent(s) include antifungal agents (e.g., amphotericin B, clotrimazole, nystatin, ketoconazole, miconazol, etc.), antibiotic agents (penicillins, cephalosporins, erythromycin, tetracycline, amino glycosides, etc.), antiviral agents (e.g, acyclovir, idoxuridine, etc.), breath fresheners (e.g.
  • antitussive agents e.g., dextromethorphan hydrochloride
  • anti-cariogenic compounds e.g., metallic salts of fluoride, sodium monofluorophosphate, stannous fluoride, amine fluorides
  • analgesic agents e.g., methylsalicylate, salicylic acid, etc.
  • local anesthetics e.g., benzocaine
  • oral antiseptics e.g., chlorhexidine and salts thereof, hexylresorcinol, dequalinium chloride, cetylpyridinium chloride
  • anti-fiammatory agents e.g., dexamethasone, betamethasone, prednisone, prednisolone, triamcinolone, hydrocortisone, etc.
  • hormonal agents oestriol
  • antiplaque agents e.g, chlorhexidine and salts thereof, octenidine, and mixtures of thy
  • the solid formulations of the invention may also include other locally active agents, such as flavorants and sweeteners.
  • flavorants and sweeteners any flavoring or food additive such as those described in Chemicals Used in Food Processing, pub 1274 by the National Academy of Sciences, pages 63-258 may be used.
  • the final product may include from about 0.1% to about 5% by weight flavorant.
  • the active agent is a liquid herbal extract.
  • the term "liquid” as used herein means that the herbal extract is sufficiently wetted to be atomized in a spray dryer.
  • the herbal extract is selected from the group consisting of: Alfalfa Leaf, Alfalfa Juice, Aloee-emodin, Andrographolide, Angelica Root, Astragalus Root, Bilberry, Black Cohosh Root, Black Walnut Leaf, Blue Cohosh Root, Burdock Root, Cascara Bark, Cats Claw Bark, Catnip Leaf, Cayenne, Chamomile Flowers, Chaste Tree Berries, Chickweed, Chinese Red Sage Root, Cranberry, Chrysophanol, Comfrey Leaf, Cramp Bark, Damiana Leaf, Dandelion Root CO, Devil's Claw Root, Diosgenin, Dong Quai Root, Dong Quai, Echinacea, Echinacea Angustifolia Root, E
  • the herbal extract is selected from the group consisting of St. John's Wort, Artichoke Leaves, and Ginseng.
  • the active agent is hygroscopic.
  • hygroscopic active agents include many herbal extracts, including St. John's Wort, Artichoke Leaves, and Ginseng.
  • the agglomerated particles in accordance with the embodiments of the present invention described above provide a number of advantages. Specifically, the agglomerated particles provide superior flow characteristics to prior art compositions. As one of ordinary skill in the art will appreciate, the superior flow characteristics provided by the embodiments of the present invention allow faster and more efficient processing for tablets, capsules, and other dosage forms. [0049] The agglomerated particles in accordance with the embodiments of the present invention also provide superior compaction characteristics to prior art compositions. As one of ordinary skill in the art will appreciate, the superior compaction characteristics provided by the embodiments of the present invention allow faster and more efficient processing for tablets, and, moreover, allow a larger percentage of active agent to be included in each tablet. For example, St.
  • John's Wort is currently marketed in 600 mg capsules, wherein each capsule includes 150 mg. of St. John's Wort extract.
  • 300 mg of St. John's Wort extract can be included in a 450 mg tablet.
  • Ginseng is currently marketed in 450 mg tablets, wherein each tablet includes 100 mg. of Ginseng extract.
  • 500 mg of Ginseng extract can be included in a 752 mg. tablet.
  • the agglomerated particles in accordance with the embodiments of the present mvention exhibit superior content uniformity when tableted than agglomerated particles that are formed by a wet granulation of silicified MCC and an active agent. This is particularly useful when tableting low dose formulations because such formulations are particularly prone to content uniformity problems.
  • the agglomerated particles in accordance with the embodiments of the present invention are particularly advantageous with respect to tablets including 100 mg or less active agent in tablets having a total tablet weight between 200 mg and 800 mg. In certain embodiments, the tablets include 50 mg or less active agent in tablets having a total tablet weight of between 200 mg and 800 mg.
  • the tablets include 10 mg or less active agent in tablets having a total tablet weight of between 50 mg and 800 mg. In still other embodiments, the tablets include 1 mg or less active agent in tablets having a total tablet weight of between 10 mg and 800 mg. In still other embodiments, the tablets include no more than about 20 % by weight active agent, preferably no more than about 10 % by weight active agent, and most preferably no more than about 1 % by weight active agent.
  • an augmented microcrystalline cellulose can be substituted for silicified MCC in the above referenced products and processes.
  • the augmented microcrystalline cellulose is a particulate agglomerate of coprocessed microcrystalline cellulose and from about 0.1% to about 20% of a compressibility augmenting agent, by weight of the microcrystalline cellulose, the microcrystalline cellulose and compressibility augmenting agent being in intimate association with each other.
  • suitable compressibility augmenting agents include pharmaceutically (or nutraceutically) acceptable metal oxides such as colloidal titanium dioxide, as well as colloidal carbon black. Surface treated metal oxides may also be used.
  • silicified microcrystalline cellulose (which includes the metal oxide silicon dioxide) is also an example of an augmented microcrystalline cellulose as defined herein.
  • pharmaceutically (or nutraceutically) acceptable metal oxides such as colloidal titanium oxide, or colloidal carbon black
  • colloidal titanium oxide or colloidal carbon black
  • agglomerated particles in accordance with the embodiments of the present invention described above are preferably manufactured using a spray dryer, it should be appreciated that other types of dryers may alternatively be used, provided that they are capable of forming the agglomerated particles described above.
  • the agglomerated particles described above may be combined with conventional tableting additives prior to tableting.
  • any generally accepted soluble or insoluble inert pharmaceutical filler (diluent) material can be included in the final product (e.g., a solid dosage form).
  • the inert pharmaceutical filler comprises a monosaccharide, a disaccharide, a polyhydric alcohol, inorganic phosphates, sulfates or carbonates, and/or mixtures thereof.
  • suitable inert pharmaceutical fillers include sucrose, dextrose, lactose, xylitol, fructose, sorbitol, calcium phosphate, calcium sulfate, calcium carbonate, "off-the-shelf microcrystalline cellulose, mixtures thereof, and the like.
  • An effective amount of any generaUy accepted pharmaceutical lubricant, including the calcium or magnesium soaps may optionally be added prior to compression into a solid dosage form.
  • the lubricant may comprise, for example, magnesium stearate in any amount of about 0.5-3% by weight of the solid dosage form.
  • the complete mixture in an amount sufficient to make a uniform batch of tablets, may then subjected to tableting in a conventional production scale tableting machine at normal compression pressures for that machine, e.g., about 1500-10,000 lbs/sq in.
  • the mixture should not be compressed to such a degree that there is subsequent difficulty in its hydration when exposed to gastric fluid.
  • the average tablet size for round tablets is preferably about 50 mg to 500 mg and for capsule-shaped tablets about 200 mg to 2000 mg.
  • other formulations prepared in accordance with the present invention may be suitably shaped for other uses or locations, such as other body cavities, e.g., periodontal pockets, surgical wounds, vaginally. It is contemplated that for certain uses, e.g., antacid tablets, vaginal tablets and possibly implants, that the tablet will be larger.
  • the tablet is coated with a sufficient amount of a hydrophobic polymer to render the formulation capable of providing a release of the medicament such that a 12 or 24 hour formulation is obtained.
  • the tablet coating may comprise an enteric coating material in addition to or instead or the hydrophobic polymer coating.
  • suitable enteric polymers include cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, polyvinylacetate phthalate, methacrylic acid copolymer, shellac, hydroxypropylmethylcellulose succinate, cellulose acetate trimellitate, and mixtures of any of the foregoing.
  • An example of a suitable commercially available enteric material is available under the trade name EudragitTM L 100-555.
  • the dosage form may be coated with a hydrophilic coating in addition to or instead of the above-mentioned coatings.
  • a hydrophilic coating is hydroxypropylmethylcellulose (e.g., Opadry®, commercially available from Colorcon, West Point, Pa.).
  • the coatings may be applied in any pharmaceutically acceptable manner known to those skilled in the art.
  • the coating is applied via a fluidized bed or in a coating pan.
  • the coated tablets may be dried, e.g., at about 60° -70° C. for about 3-4 hours in a coating pan.
  • the solvent for the hydrophobic polymer or enteric coating may be organic, aqueous, or a mixture of an organic and an aqueous solvent.
  • the organic sqlvents may be, e.g., isopropyl alcohol, ethanol, and the like, with or without water.
  • the coatings which may be optionally applied to the compressed solid dosage form of the mvention may comprise from about 0.5% to about 30% by weight of the final solid dosage form.
  • a support platform is applied to the tablets manufactured in accordance with the present invention.
  • Suitable support platforms are well known to those skilled in the art.
  • An example of suitable support platforms is set forth, e.g., in U.S. Pat. No. 4,839,177, hereby incorporated by reference.
  • the support platform partially coats the tablet, and consists of a polymeric material insoluble in aqueous liquids.
  • the support platform may, for example, be designed to maintain its impermeability characteristics during the transfer of the therapeuticaUy active medicament.
  • the support platform may be applied to the tablets, e.g., via compression coating onto part of the tablet surface, by spray coating the polymeric materials comprising the support platform onto all or part of the tablet surface, or by immersing the tablets in a solution of the polymeric materials.
  • the support platform may have a thickness of, e.g., about 2 mm if applied by compression, and about 10 ⁇ m if applied via spray-coating or immersion-coating.
  • a hydrophobic polymer or enteric coating is applied to the tablets, the tablets are coated to a weight gain from about 1% to about 20%, and in certain embodiments preferably from about 5% to about 10%.
  • Materials useful in the hydrophobic coatings and support platforms of the present invention include derivatives of acrylic acid (such as esters of acrylic acid, methacrylic acid, and copolymers thereof) celluloses and derivatives thereof (such as ethylcellulose), polyvinylalcohols, and the like.
  • an additional dose of the active agent may be included in either the hydrophobic or enteric coating, or in an additional overcoating coated on the outer surface of the tablet core (without the hydrophobic or enteric coating) or as a second coating layer coated on the surface of the base coating comprising the hydrophobic or enteric coating material.
  • This may be desired when, for example, a loading dose of a therapeuticaUy active agent is needed to provide therapeuticaUy effective blood levels of the active agent when the formulation is first exposed to gastric fluid.
  • the loading dose of active agent included in the coating layer may be, e.g., from about 10% to about 40% of the total amount of medicament included in the formulation.
  • the tablets of the present mvention may also contain effective amounts of coloring agents, (e.g., titanium dioxide, F.D. & C. and D. & C. dyes; see the Kirk-Othmer Encyclopedia of Chemical Technology, Vol. 5, pp. 857-884, hereby incorporated by reference), stabilizers, binders, odor controlling agents, and preservatives.
  • coloring agents e.g., titanium dioxide, F.D. & C. and D. & C. dyes; see the Kirk-Othmer Encyclopedia of Chemical Technology, Vol. 5, pp. 857-884, hereby incorporated by reference
  • stabilizers e.g., binders, odor controlling agents, and preservatives.
  • the agglomerated particles of active agent/silicified MCC (with or without silicon dioxide) can be utilized in other applications wherein it is not compressed.
  • the agglomerated particles can be filled into capsules.
  • the agglomerated particles can further be molded into shapes other than those typically associated with tablets.
  • the agglomerated particles can be molded to "fit" into a particular area in an environment of use (e.g., an implant). AU such uses would be contemplated by those skilled in the art and are deemed to be encompassed within the scope of the appended claims.
  • the artichoke leaves extract is in the form of a liquid extract (specifically, it is in a water solvent).
  • This liquid extract was placed into the fluid feed system of a spray dryer, atomized, and combined with the Prosolv SMCC 90 and colloidal silicon dioxide in the drying chamber of the spray dryer.
  • the Prosolv SMCC 90 and colloidal silicon dioxide both dry were homogenized (in a mixer), and then fed into the drying chamber along with the recycled fines from the collection system.
  • the agglomerated particles collected from the collection system provided a yield of 95.2 kg, with the following composition:
  • a mixture of artichoke leaves extract/glucose/maltodextrin/silicon dioxide was prepared with the following ingredients:
  • the artichoke leaves extract is in the form of a liquid extract (specifically, it is in a water solvent).
  • This liquid extract was placed into the fluid feed system of a spray dryer, atomized, and combined with the 20.9 g of colloidal silicon dioxide in the drying chamber of the spray dryer. The resultant agglomerated particles were then mixed with the glucose, maltodextrin, and the remaining 11.5 g of colloidal silicon dioxide in a mixer.
  • the ginseng extract is in the form of a liquid extract (specifically, it is in an Ethanol 60 % (V/V) solvent).
  • This liquid extract was placed into the fluid feed system of a spray dryer, atomized, and combined with the Prosolv SMCC 90 and colloidal silicon dioxide in the drying chamber of the spray dryer.
  • the Prosolv SMCC and colloidal silicon dioxide both dry were homogenized (in a mixer), and then fed into the drying chamber along with the recycled fines from the collection system.
  • the agglomerated particles collected from the collection system provided a yield of 94.4 kg, with the following composition:
  • Ginseng extract (Extr. Ginseng e rad. spir. spiss.)
  • a mixture of ginseng extract/maltodextrin was prepared with the following ingredients:
  • the ginseng extract is in the form of a liquid extract (specifically, it is in an Ethanol 70 % (V/V) solvent).
  • the liquid extract was mixed with the maltodextrin in a mixture, then dried in a vacuum belt dryer and milled.
  • the resultant product had a yield of 517.5 kg, with the following composition:
  • Agglomerated particles of St. John' s Wort extract/Prosolv SMCC 90 were prepared with the following ingredients:
  • the St. John's Wort extract is in the form of a liquid extract (specifically, it is in an Ethanol 60 % (m/m) solvent).
  • This liquid extract was placed into the fluid feed system of a spray dryer, atomized, and combined with the Prosolv SMCC 90 in the drying chamber of the spray dryer.
  • dry Prosolv SMCC dry was fed into the drying chamber along with the recycled fines from the collection system.
  • the agglomerated particles collected from the collection system provided a yield of 138.8 kg, with the following composition:
  • Agglomerated particles of St. John's Wort extract/Prosolv SMCC 90 were prepared with the following ingredients:
  • the St. John's Wort extract is in the form of a liquid extract (specifically, it is in an Ethanol 60 % (m/m) solvent).
  • This liquid extract was placed into the fluid feed system of a spray dryer, atomized, and combined with the Prosolv SMCC 90 in the drying chamber of the spray dryer.
  • dry Prosolv SMCC dry was fed into the drying chamber along with the recycled fines from the collection system.
  • the agglomerated particles collected from the collection system provided a yield of 176.6 kg, with the following composition:
  • Silicon dioxide highly dispersed (Aerosil), Ph. Eur 9.5
  • the St. John's Wort extract is in the form of a liquid extract (specifically, it is in an Ethanol 60 % (m/m) solvent).
  • This liquid extract was placed into the fluid feed system of a spray dryer, atomized, and combined with the Prosolv SMCC 90 and colloidal silicon dioxide in the drying chamber of the spray dryer.
  • the Prosolv SMCC and colloidal silicon dioxide both dry were homogenized (in a mixer), and then fed into the drying chamber along with the recycled fines from the collection system.
  • the agglomerated particles collected from the collection system provided a yield of 152.8 kg, with the following composition:
  • Silicon dioxide highly dispersed (Aerosil), Ph. Eur. 104.6 Maltodextrin Ph. Eur. 100.0
  • the St. John's Wort extract is in the form of a liquid extract (specifically, it is in a Ethanol 60 % (m/m) solvent).
  • This liquid extract was placed into the fluid feed system of a spray dryer, atomized, and combined with the colloidal silicon dioxide in the drying chamber of the spray dryer. The resultant agglomerated particles were then mixed with the maltodextrin in a mixer.
  • the St. John's Wort extract is in the form of a liquid extract (specifically, it is in a Ethanol 60 % (m/m) solvent).
  • This liquid extract was placed into the fluid feed system of a spray dryer, atomized, and combined with the colloidal silicon dioxide (Batches 1-3) in the drying chamber of the spray dryer. The resultant agglomerated particles were then mixed with the maltodextrin (Batches 1-2) in a mixer.
  • Example 6 the agglomerated particles of Example 3 are mixed in a Patterson- Kelley twin-shell V-blender with MgStearate and Maltodextrin to form a mixture with the following composition:
  • Example 7 the agglomerated particles of Example 3 are mixed in a Patterson- Kelley twin-shell V-blender with MgStearate and Prosolv SMCC 50 to form a mixture with the following composition:
  • Example E the mixture Example D is mixed in a Patter son-Kelley twin-shell V- blender with MgStearate and Prosolv SMCC 50 to form a mixture with the following composition:
  • Example 8 the agglomerated particles of Example 3 are mixed in a Patterson- Kelley twin-shell V-blender with MgStearate to form a mixture with the following composition: Ingredient amount g) percentage
  • Example F the mixture of Example D is mixed in a Patterson-KeUey twin-shell V-blender with MgStearate to form a mixture with the following composition:
  • Example 9-1 the agglomerated particles of Example 5 are mixed in a Patterson- KeUey twin-shell V-blender with Explotab for ten minutes and then MgStearate is added to the mixture and blended for 5 minutes to form a mixture with the following composition:
  • Example 9-2 the agglomerated particles of Example 5 are mixed in a Patterson- KeUey twin-shell V-blender with Explotab for ten minutes and then MgStearate is added to the mixture and blended for 5 minutes to form a mixture with the following composition:
  • Example G the mixture of the of Example A is mixed in a Patterson-KeUey twin-shell V-blender with Prosolv SMCC 50, sodium stearyl fumate and MgStearate to form a mixture with the following composition:
  • Example 10 was produced in the same manner as Examples 3 and 4, except that the agglomerated particles collected from the collection system had the following composition:
  • Example 11 was produced in the same manner as Examples 3 and 4, except that the agglomerated particles collected from the collection system had the following composition:
  • Example 12 the agglomerated particles of Example 4 are mixed in a Patterson- KeUey twin-shell V-blender with Explotab for ten minutes and then MgStearate is added to the mixture and blended for 5 minutes to form a mixture with the following composition:
  • Example H the mixture of Comparative Example D is mixed in a Patterson- KeUey twin-shell V-blender with Explotab for ten minutes and then MgStearate is added to the mixture and blended for 5 minutes to form a mixture with the following composition:
  • Example 13 the agglomerated particles of Example 11 are mixed in a Patterson- KeUey twin-shell V-blender with Explotab for ten minutes and then MgStearate is added to the mixture and blended for 5 minutes to form a mixture with the following composition:
  • Example 14 the agglomerated particles of Example 10 are mixed in a Patterson- KeUey twin-shell V-blender with Explotab for ten minutes and then MgStearate is added to the mixture and blended for 5 minutes to form a mixture with the following composition :
  • Example I the mixture of Example B is mixed in a Patterson-KeUey twin-shell V-blender for five minutes with Prosolv SMCC 50, sodium stearyl fumate and MgStearate to form a mixture with the following composition:
  • Example B 264 66.00% sodium stearyl fumate 8 2.00% talc 8 2.00%
  • Example J the mixture of Example B is mixed in a Patterson-KeUey twin-shell V-blender with Prosolv SMCC 50 to form a mixture with the following composition: Ingredient amountCg) percentage
  • Example 15 the agglomerated particles of Example 2 are mixed in a Patterson- KeUey twin-shell V-blender with sodium stearyl fumate and MgStearate for five minutes to form a mixture with the following composition:
  • Example 2 384 96.00% sodium stearyl fumate 8 2.00% talc 8 ' 2.00%
  • Example 16 the agglomerated particles of Example 1 are mixed in a Patterson- KeUey twin-shell V-blender with sodium stearyl fumate and MgStearate for five minutes to form a mixture with the following composition:
  • Example 1 384 96.00% sodium stearyl fumate 8 2.00% talc 8 2.00%
  • Figure 2 is a graph of volume flow (ml/s) as a function of aperture size (mm) for the St. John's Wort compositions of Examples 3 and D.
  • the compositions of Example 3 and Example D each had an initial mass of 75.00g and a bulk density 0.465g/ml.
  • the flodex cup diameter used for each example was 5.7cm.
  • the relative humidity during the testing of Example 3 was 65 % RH, whereas the relative humidity during the testing of Example D was 45 % RH.
  • the St. John's Wort extract coprocessed with silicified MCC in accordance with the present invention exhibits superior flow characteristics to the St. John's Wort which is not coprocessed with silicified MCC (Comparative Example D).
  • the St. John's Wort of Example D that was co-sprayed dried with silicon dioxide, and thereafter mixed with maltodextrin was unable to flow though a 16 mm aperture (in other words, Example D bridged at 16 mm).
  • the St. John's Wort extract of Example 3 did not bridge until 7 mm, despite the fact that the testing of Example 3 were conducted at a higher relative humidity.
  • Figure 3 is a graph of volume flow (ml/s) as a function of aperture size (mm) for the St. John's Wort compositions of Examples 6, 7, and E.
  • the flow data was collected using a Hanson FlodexTM (Hanson Research Instruments, Inc.).
  • the flodex cup diameter used for each composition was 5.7cm, and each composition had an initial mass of 75.00 g.
  • the composition of Example E had a bulk density of 0.476 g/ml
  • the composition of Example 6 had a bulk density of 0.468 g/ml
  • the composition of Example 7 had a bulk density of 0.432 g/ml. All tests were conducted on the same day, with the relative humidity ranging from 45 % to 48 % RH.
  • Example 3 when the St. John's Wort composition of Example 3 is further mixed with maltodextrin and MgStearate (Example 6) or with silicified MCC and Mg Stearate (Example 7), the resultant formulation continued to flow even through the minimum aperture of 4 mm.
  • Figure 4 is a graph of moisture uptake for the St. John's wort compositions. Twenty-five gram samples of Examples 4 and D were maintained at 25 C and 40% RH. As shown in Figure 4, the St. John's Wort extract that was co-sprayed dried with silicified MCC (Example 4) has acceptable moisture uptake when compared the St. John's Wort extract which was not co-spray dried with silicified MCC (Example D). In general, it is considered desirable to have acceptable moisture uptake because unacceptably high levels of moisture absorption may lead to stability problems with the final dosage form, and can cause adverse affects during tableting such as caking.
  • Figures 5 through 7 are graphs of tablet hardness as a function of compaction force for Examples 7-9, 12-14, and H.
  • Figure 5 is a graph of tablet hardness as a function of compaction force for the compositions of Examples 7 and E. Each composition was tableted in a caplet shaped 0.250" x 0.750", and the tablets had a target tablet mass of 550 mg.
  • the compaction data for each formulation is set forth below: Compaction Data For Example E
  • the St. John's Wort co-spray dried with 30 % silicified MCC exhibits superior compaction and hardness characteristics, when tableted with MgStearate and silicified MCC (Example 7), than a St. John's Wort extract that is tableted in the same mamier, but is not co-spray dried with silicified MCC (Example E).
  • Figure 6 is a graph of tablet hardness as a function of compaction force for the compositions of Examples 8, 9-1, and F. Each composition was tableted in a caplet shaped 0.250" x 0.750", and the tablets had a target tablet mass of 550 mg.
  • the compaction data for each formulation is set forth below: Compaction Data For Example 8
  • the St. John's Wort co-spray dried with 30 % silicified MCC exhibits superior compaction and hardness characteristics, when tableted with MgStearate (Example 8), than a St. John's Wort extract that is tableted in the same maimer, but is not co-spray dried with silicified MCC (Example F).
  • Example 8 a St. John's Wort extract that is tableted in the same maimer, but is not co-spray dried with silicified MCC
  • Example 9-1 colloidal silicon dioxide
  • Figure 7 is a graph of tablet hardness as a function of compaction force for the compositions of Examples 9-2, 12, 13, 14, and H. Each composition was tableted in a caplet shaped 0.2230" x 0.5670"and the tablets had a target tablet mass of 441 mg.
  • the compaction data for each formulation is set forth below:
  • Figure 7 shows a comparison of the compaction characteristics of i) St. John's Wort extract co-spray dried with 24.9% silicified MCC and 5.2 % silicon dioxide (Example 5), ii) St. John's Wort extract co-spray dried with 31.7 % silicified MCC (Example 4); iii) St. John's Wort extract which is not co-spray dried with silicified MCC (Example C); iv) St. John's Wort extract co-spray dried with 25 % silicified MCC and no silicon dioxide (Example 11); and v) St.
  • John's Wort extract co-spray dried with 20 % silicified MCC (Example 10); wherein each formulation was blended with 3 % Explotab and 0.5% MgStearate to obtain the mixture of Examples 9-2, 12, H, 13, and 14 respectively, and then tableted.
  • Example 9-2 As shown in Figure 7, the formulation of Example 9-2 (co-spray dried with silicified MCC and silicon dioxide) provided the best compaction characteristics.
  • the compaction characteristics of the formulation of Example 12 (co-spray dried with 31 % silicified MCC) were far worse than the formulation of Example 9-2, but still significantly better than Comparative Example H (not co-spray dried with silicified MCC).
  • Figure 8 is a graph of moisture uptake for the Ginseng extract compositions of Examples 2 and B. Twenty-five gram samples of Examples B and 2 were maintained at 25 C and 40% RH. As shown in Figure 8, the ginseng extract that was co-sprayed dried with silicified MCC (Example 2) absorbed about 40% less moisture over 240 minutes as the ginseng extract which was not co-spray dried with silicified MCC. However, in view of the fact that the composition of Example 2 includes 17.5 grams of Ginseng extract (0.70*25), whereas the composition of Example B includes 24.175 g of Ginseng extract (0.967*25), a "weight corrected" plot for Example 2 is also included in Figure 8.
  • Example 2 with Weight Correction The data for "Example 2 with Weight Correction" in Figure 8 was obtained by multiplying each data point of Example 2 by 24.175/17.5. Based upon the above, the Ginseng extract that was co-sprayed dried with silicified MCC (Example 2) has acceptable moisture uptake when compared the St. John's Wort extract which was not co-spray dried with silicified MCC (Example B)
  • Figure 9 is a graph of mass flow (g/s) as a function of aperture size (mm) for the Ginseng composition of Example 2.
  • Flow data was collected using a Hanson FlodexTM (Hanson Research Instruments, Inc.). Flow data was collected for the composition of Example 2 and the composition of Example B blended with 30% Prosolv SMCC 50 (Example J). It should be appreciated that in view of the fact that the composition of Example B is 96.7% ginseng extract, it was blended with 30 % Prosolv SMCC 50 for purposes of comparison with Example 2, which contains 70% ginseng extract.
  • the flodex cup diameter used for each composition was 5.7cm, each composition had an initial mass of 95.6 g, and the experiment was conducted at 62 % RH.
  • the flow data for Example 2 is as follows: Flow Data For Example : 2
  • Example J The composition of Example J bridged at 30 mm, and, therefore, is not shown in Figure 9. h contrast, the Ginseng composition of Example 2 bridged at 8 mm. As such, the composition of Example 2 provides superior flow characteristics as compared with the composition of Example B even when Example B is blended with 30 % Prosolv SMCC 50 in an attempt to improve its flow characteristics.
  • Figure 10 is a graph of tablet hardness as a function of compaction force for the compositions of Examples I and 15. Each composition was tableted in a caplet shaped 0.750" x 0.3125", and the tablets had a target tablet mass of 800 mg.
  • the compaction data for each formulation is set forth below:
  • the Ginseng extract co-spray dried with 25 % silicified MCC and 5% colloidal silicon dioxide exhibits superior compaction and hardness characteristics, when tableted with talc and sodium stearyl fumarate (Example 15), than a Ginseng extract that is tableted in the same manner, but is not co-spray dried with silicified MCC (Example I).
  • Figure 11 is a graph of mass flow (g/s) as a function of aperture size (mm) for the Artichoke compositions of Examples 1 and A. Flow data was collected using a Hanson FlodexTM (Hanson Research Instruments, Inc.). The compositions of Example 1 and Example A each had an initial mass of 95.6 g. The flodex cup diameter used for each example was 5.7cm, and the test was conducted at 24 % RH.
  • Aperture time mass time mass time mass flow rate (mm) (s) (g) (s) (g) (s) (g) (g) (g-s-1)
  • Aperture time mass time mass time mass flow rate (mm) (s) (g) (s) (g) (s) (g) (g) (g-s-1)
  • Example 1 the Artichoke extract coprocessed with silicified MCC in accordance with the present invention (Example 1) exhibits equivalent flow characteristics to the artichoke extract which is not coprocessed with silicified MCC (Comparative Example A). It should be noted that equivalent flow characteristics were obtain despite the fact that the formulation of Example 1 had 70 % artichoke leaves extract as compared to 51.6 % artichoke leaves extract in Example A.
  • Figure 12 is a graph of moisture uptake for artichoke extract. Twenty-five gram samples of Examples 1 and A were maintained at 25° C and 40% RH. As shown in Figure 12, the artichoke extract that was co-sprayed dried with silicified MCC (Example 1) absorbed over twice as much moisture over 800 minutes than the artichoke extract which was not co-spray dried with silicified MCC. However, despite the fact that the extract of Example 1 absorbed more moisture than the extract of Example A, both extracts were able to flow at aperture sizes as small as 4 mm as demonstrated in Figure 11.
  • Figure 13 is a graph of tablet hardness as a function of compaction force for the compositions of Examples 16 and G .
  • Each composition was tableted in a caplet shaped 0.750" x 0.3125", and the tablets had a target tablet mass of 800 mg.
  • the compaction data for each formulation is set forth below:
  • the artichoke extract co-spray dried with 25 % silicified MCC and 5 % colloidal silicon dioxide exhibits superior compaction and hardness characteristics, when tableted with talc and sodium stearyl fumarate (Example 16), than a Ginseng extract that is tableted in the same manner, but is not co-spray dried with silicified MCC (Example G).
  • the compaction data set forth above indicates that since the formulations of Examples 7-9, 12, 15 and 16 exhibit superior compaction characteristics to comparative examples E, F, H, I, and K, the formulations in accordance with these examples can be compressed into smaller tablets than their corresponding comparative examples.
  • St. John's Wort is currently marketed in 600 mg capsules, wherein each capsule includes 150 mg. of St. John's Wort extract, hi contrast, as shown in the table below, with the formulations of Examples 8 and 9-2, 300 mg of St. John's Wort extract can be included in a 450 mg. tablet (normalizing the compaction data for these examples to a 450 mg. tablet):
  • Ginseng is currently marketed in 450 mg tablets, wherein each tablet includes 100 mg. of Ginseng extract.
  • 500 mg of Ginseng extract can be included in a 752 mg.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention a trait à une forme dosifiée solide comprenant un principe actif et de la cellulose microcristalline silicifiée. La préparation de la forme dosifiée consiste à: a) combiner un principe actif humide avec de la cellulose microcristalline silicifiée dans un sécheur afin de former des particules agglomérées ; et b) incorporer les particules agglomérées dans la forme dosifiée solide. Dans certains modes de réalisation préférés, l'étape b consiste à combiner ladite cellulose microcristalline silicifiée, ledit agent actif, et du silice sublimé dans un sécheur. De préférence, le sécheur est un sécheur atomiseur, et dans certains modes de réalisation, le principe actif peut être un extrait d'herbes. La figure 1 est un schéma fonctionnel d'un sécheur atomiseur comprenant un principe actif fluide et une source de cellulose microcristalline silicifiée.
PCT/US2001/044928 2001-11-29 2001-11-29 Particules agglomerees comprenant un principe actif cotraite avec de la cellulose microcristalline silicifiee WO2003047551A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01274926A EP1509204A4 (fr) 2001-11-29 2001-11-29 Particules agglomerees comprenant un principe actif cotraite avec de la cellulose microcristalline silicifiee
AU2002219964A AU2002219964A1 (en) 2001-11-29 2001-11-29 Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
PCT/US2001/044928 WO2003047551A1 (fr) 2001-11-29 2001-11-29 Particules agglomerees comprenant un principe actif cotraite avec de la cellulose microcristalline silicifiee

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/044928 WO2003047551A1 (fr) 2001-11-29 2001-11-29 Particules agglomerees comprenant un principe actif cotraite avec de la cellulose microcristalline silicifiee

Publications (1)

Publication Number Publication Date
WO2003047551A1 true WO2003047551A1 (fr) 2003-06-12

Family

ID=21743033

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/044928 WO2003047551A1 (fr) 2001-11-29 2001-11-29 Particules agglomerees comprenant un principe actif cotraite avec de la cellulose microcristalline silicifiee

Country Status (3)

Country Link
EP (1) EP1509204A4 (fr)
AU (1) AU2002219964A1 (fr)
WO (1) WO2003047551A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008035354A1 (fr) * 2006-09-21 2008-03-27 Unijules Life Sciences Ltd. Pastilles d'extraits d'herbes et son procédé de préparation
WO2008059522A2 (fr) * 2006-09-28 2008-05-22 Unijules Life Sciences Ltd Formes posologiques d'administration contrôlée de médicament gastro-intestinale à base d'herbe comprenant des pastilles et leur procédé de préparation
DE102007045686A1 (de) * 2007-09-24 2009-04-02 J. Rettenmaier & Söhne Gmbh + Co. Kg Verfahren zur Herstellung frei fließender, pulverförmiger Extrakte mit Hilfe der Wirbelschicht Trocknung
US20110135760A1 (en) * 2007-08-16 2011-06-09 Virdis Pharmaceutical Limited Use of Extracts or Materials Extracted From Piper Cubeba L. as an Effective Component in a Drug for the Treatment of Cancer Diseases
US8268349B2 (en) 2003-08-28 2012-09-18 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8470347B2 (en) 2000-05-30 2013-06-25 AbbVie Deutschland GmbH and Co KG Self-emulsifying active substance formulation and use of this formulation
US8663684B2 (en) 2008-09-19 2014-03-04 Molkerei Meggle Wasserburg Gmbh & Co. Kg Lactose and cellulose-based tableting aid
CN104472880A (zh) * 2014-12-12 2015-04-01 四川乾坤生物科技有限公司 一种兽药组合物及其制备方法和用途
WO2016128386A1 (fr) 2015-02-09 2016-08-18 Vereeken Jose Formulation multiparticulaire comprenant des extraits de plante
US9891239B2 (en) 2007-02-23 2018-02-13 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
US10039718B2 (en) 2008-05-02 2018-08-07 Gilead Sciences, Inc. Use of solid carrier particles to improve the processability of a pharmaceutical agent
US11447510B2 (en) 2017-10-09 2022-09-20 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11564935B2 (en) 2019-04-17 2023-01-31 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022310161A1 (en) 2021-07-10 2024-01-25 Auxilius Pharma Spolka Z Ograniczona Odpowiedzialnoscia Modified release nicorandil compound formulations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466452A (en) * 1991-02-28 1995-11-14 Phytopharm Ltd. Pharmaceutical compositions for the treatment of skin disorders
US5798101A (en) * 1997-01-22 1998-08-25 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
WO1999015155A1 (fr) * 1997-09-19 1999-04-01 Leiras Oy Preparation pharmaceutique comprenant du clodronate en tant que principe actif et de la cellulose microcristalline silicifiee en tant qu'excipient
US6190696B1 (en) * 1998-06-08 2001-02-20 Pieter J. Groenewoud Stabilized thyroxine medications

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US6117451A (en) * 1998-08-25 2000-09-12 Pharmalogix, Inc. Direct compression metformin hydrochloride tablets
US6399101B1 (en) * 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466452A (en) * 1991-02-28 1995-11-14 Phytopharm Ltd. Pharmaceutical compositions for the treatment of skin disorders
US5798101A (en) * 1997-01-22 1998-08-25 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
WO1999015155A1 (fr) * 1997-09-19 1999-04-01 Leiras Oy Preparation pharmaceutique comprenant du clodronate en tant que principe actif et de la cellulose microcristalline silicifiee en tant qu'excipient
US6190696B1 (en) * 1998-06-08 2001-02-20 Pieter J. Groenewoud Stabilized thyroxine medications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1509204A4 *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470347B2 (en) 2000-05-30 2013-06-25 AbbVie Deutschland GmbH and Co KG Self-emulsifying active substance formulation and use of this formulation
US8399015B2 (en) 2003-08-28 2013-03-19 Abbvie Inc. Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8691878B2 (en) 2003-08-28 2014-04-08 Abbvie Inc. Solid pharmaceutical dosage form
US8333990B2 (en) 2003-08-28 2012-12-18 Abbott Laboratories Solid pharmaceutical dosage form
US8268349B2 (en) 2003-08-28 2012-09-18 Abbott Laboratories Solid pharmaceutical dosage form
US8309613B2 (en) 2003-08-28 2012-11-13 Abbvie Inc. Solid pharmaceutical dosage form
WO2008035354A1 (fr) * 2006-09-21 2008-03-27 Unijules Life Sciences Ltd. Pastilles d'extraits d'herbes et son procédé de préparation
WO2008059522A3 (fr) * 2006-09-28 2008-07-10 Unijules Life Sciences Ltd Formes posologiques d'administration contrôlée de médicament gastro-intestinale à base d'herbe comprenant des pastilles et leur procédé de préparation
WO2008059522A2 (fr) * 2006-09-28 2008-05-22 Unijules Life Sciences Ltd Formes posologiques d'administration contrôlée de médicament gastro-intestinale à base d'herbe comprenant des pastilles et leur procédé de préparation
US9891239B2 (en) 2007-02-23 2018-02-13 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
US20110135760A1 (en) * 2007-08-16 2011-06-09 Virdis Pharmaceutical Limited Use of Extracts or Materials Extracted From Piper Cubeba L. as an Effective Component in a Drug for the Treatment of Cancer Diseases
US9248156B2 (en) 2007-08-16 2016-02-02 Viridis Pharmaceutical Limited Use of extracts or materials extracted from Piper cubeba L. as an effective component in a drug for the treatment of cancer diseases
US8404286B2 (en) * 2007-08-16 2013-03-26 Viridis Pharmaceutical Limited Use of extracts or of extract compounds from Piper cubeba L. as active components in a medicament for the treatment of cancer
DE102007045686A1 (de) * 2007-09-24 2009-04-02 J. Rettenmaier & Söhne Gmbh + Co. Kg Verfahren zur Herstellung frei fließender, pulverförmiger Extrakte mit Hilfe der Wirbelschicht Trocknung
US10039718B2 (en) 2008-05-02 2018-08-07 Gilead Sciences, Inc. Use of solid carrier particles to improve the processability of a pharmaceutical agent
US8663684B2 (en) 2008-09-19 2014-03-04 Molkerei Meggle Wasserburg Gmbh & Co. Kg Lactose and cellulose-based tableting aid
CN104472880A (zh) * 2014-12-12 2015-04-01 四川乾坤生物科技有限公司 一种兽药组合物及其制备方法和用途
WO2016128386A1 (fr) 2015-02-09 2016-08-18 Vereeken Jose Formulation multiparticulaire comprenant des extraits de plante
US11447510B2 (en) 2017-10-09 2022-09-20 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11505564B2 (en) 2017-10-09 2022-11-22 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11629159B2 (en) 2017-10-09 2023-04-18 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11851451B2 (en) 2017-10-09 2023-12-26 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11939346B2 (en) 2017-10-09 2024-03-26 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11564935B2 (en) 2019-04-17 2023-01-31 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US11738035B2 (en) 2019-04-17 2023-08-29 Compass Pathfinder Limited Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

Also Published As

Publication number Publication date
AU2002219964A1 (en) 2003-06-17
EP1509204A4 (fr) 2005-07-13
EP1509204A1 (fr) 2005-03-02

Similar Documents

Publication Publication Date Title
US7179488B2 (en) Process for co-spray drying liquid herbal extracts with dry silicified MCC
US20030206978A1 (en) Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US20070011904A1 (en) Process for co-spray drying agents with dry silicified MCC
US20060228487A1 (en) Methods of combining active agents with augmented microcrystalline cellulose
US20080268036A1 (en) Co-processing of active pharmaceutical/nutraceutical ingredients
EP1481211B1 (fr) Procede de sechage par co-pulverisation d'extraits fluides de plantes et de cellulose microcristalline silicifiee
EP1287823B1 (fr) Excipient pharmaceutique à compressibilité améliorée
US6471994B1 (en) Pharmaceutical excipient having improved compressibility
EP1509204A1 (fr) Particules agglomerees comprenant un principe actif cotraite avec de la cellulose microcristalline silicifiee
AU2002301259C1 (en) Simethicone solid oral dosage form
EP0749300B1 (fr) Excipient pharmaceutique a compressibilite amelioree
KR101612073B1 (ko) 신속 용해 고체 투약 제형
EP0387885A2 (fr) Comprimé de cholestyramine à compression directe et revêtement, exempte de solvant, pour cela
US20070148211A1 (en) Processes for making particle-based pharmaceutical formulations for oral administration
WO2001013894A1 (fr) Comprime de gabapentine a proprietes physiques et chimiques ameliorees, et son procede de fabrication
DE69719083T2 (de) Neuartige orale Zubereitungen von Calcitonin
CN1257705A (zh) 用于压制片剂、丸剂和糖衣片的可流动药物前体产物及其制备方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001274926

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001274926

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载